Brimonidine Tartrate + Timolol Maleate 0.2%+0.5% Suppliers & Bulk Manufacturers

Available Forms: Eye Drops

Available Strengths: 0.2%+0.5%

Reference Brands: Combigan (USA/EU)

Category: Opthalmology

Combigan is a fixed-dose combination ophthalmic solution that combines an α₂-adrenergic agonist (brimonidine) with a non-selective β-adrenergic blocker (timolol) to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Brimonidine decreases aqueous humour production and increases uveoscleral outflow, while timolol reduces aqueous humour formation.

Product Description:

This fixed combination pairs brimonidine, an alpha-2 agonist, with timolol, a non-selective beta-blocker. Both reduce the production of aqueous humour, but through different receptors, and timolol adds no effect on outflow while brimonidine increases uveoscleral outflow — so the combination lowers pressure more than either alone. Combining them in one bottle also removes the washout problem, where a second drop instilled too soon dilutes the first.

It is used twice daily in open-angle glaucoma or ocular hypertension where one agent is not enough. Fewer drops and one bottle improve adherence, which matters in a disease where patients feel nothing and stop treatment. The trade-off is that both components' adverse effects are unavoidable together: local allergy from brimonidine, and timolol's systemic effects — bronchospasm, bradycardia, masking of hypoglycaemia — from the substantial fraction of each drop that drains into the nose and is absorbed. It is contraindicated in asthma, severe COPD, marked bradycardia and heart block, and in infants and young children.

Sourcing notes. Off patent, with generics available. Preservative-free unit-dose versions exist and are in demand for patients with ocular surface disease, who are common in long-treated glaucoma. Buyers should state preserved or preservative-free and the presentation.